Nomura Holdings’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.8M | Sell |
114,355
-2,062
| -2% | -$408K | 0.06% | 215 |
|
|
2025
Q4 | $22M | Sell |
116,417
-4,946
| -4% | -$950K | 0.03% | 299 |
|
|
2025
Q3 | $21.5M | Buy |
+121,363
| New | +$18M | 0.03% | 301 |
|
|
2022
Q3 | – | Sell |
-10,048
| Closed | -$565K | – | 1838 |
|
|
2022
Q2 | $565K | Buy |
10,048
+6,281
| +167% | +$356K | ﹤0.01% | 1094 |
|
|
2022
Q1 | $275K | Sell |
3,767
-37,983
| -91% | -$2.76M | ﹤0.01% | 1476 |
|
|
2021
Q4 | $4.06M | Buy |
41,750
+33,334
| +396% | +$3.08M | 0.01% | 772 |
|
|
2021
Q3 | $710K | Buy |
8,416
+2,405
| +40% | +$186K | ﹤0.01% | 1267 |
|
|
2021
Q2 | $494K | Sell |
6,011
-32,461
| -84% | -$2.7M | ﹤0.01% | 1358 |
|
|
2021
Q1 | $3.67M | Buy |
38,472
+24,393
| +173% | +$2.31M | 0.01% | 656 |
|
|
2020
Q4 | $873K | Sell |
14,079
-9,966
| -41% | -$568K | ﹤0.01% | 1079 |
|
|
2020
Q3 | $1.43M | Buy |
24,045
+18,915
| +369% | +$1.29M | ﹤0.01% | 734 |
|
|
2020
Q2 | $358K | Sell |
5,130
-4,408
| -46% | -$279K | ﹤0.01% | 922 |
|
|
2020
Q1 | $430K | Buy |
+9,538
| New | +$541K | ﹤0.01% | 685 |
|
|
2019
Q4 | – | Sell |
-12,035
| Closed | -$733K | – | 1224 |
|
|
2019
Q3 | $733K | Buy |
12,035
+12
| +0.1% | +$753 | ﹤0.01% | 901 |
|
|
2019
Q2 | $861K | Sell |
12,023
-24,045
| -67% | -$1.77M | ﹤0.01% | 871 |
|
|
2019
Q1 | $2.79M | Sell |
36,068
-16,831
| -32% | -$1.28M | 0.01% | 586 |
|
|
2018
Q4 | $4.46M | Buy |
52,899
+44,400
| +522% | +$4.73M | 0.02% | 537 |
|
|
2018
Q3 | $1.45M | Buy |
8,499
+484
| +6% | +$73K | 0.01% | 811 |
|
|
2018
Q2 | $1.04M | Buy |
+8,015
| New | +$894K | ﹤0.01% | 862 |
|
|
2015
Q2 | – | Sell |
-6,874
| Closed | -$326K | – | 1908 |
|
|
2015
Q1 | $326K | Sell |
6,874
-1,651
| -19% | -$63.3K | ﹤0.01% | 1283 |
|
|
2014
Q4 | $288K | Sell |
8,525
-10,110
| -54% | -$329K | ﹤0.01% | 1922 |
|
|
2014
Q3 | $573K | Buy |
18,635
+1,478
| +9% | +$49.1K | ﹤0.01% | 1729 |
|
|
2014
Q2 | $670K | Buy |
17,157
+2,504
| +17% | +$102K | ﹤0.01% | 1630 |
|
|
2014
Q1 | $612K | Buy |
14,653
+8,238
| +128% | +$343K | ﹤0.01% | 1685 |
|
|
2013
Q4 | $211K | Buy |
+6,415
| New | +$209K | ﹤0.01% | 1735 |
|
|
2013
Q3 | – | Sell |
-21,222
| Closed | -$497K | – | 2488 |
|
|
2013
Q2 | $497K | Buy |
+21,222
| New | +$382K | ﹤0.01% | 1326 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
Nomura Holdings's LGND Position: Q1 2026 in Review
Nomura Holdings reduced its Ligand Pharmaceuticals (LGND) stake by 1.8% in Q1 2026, selling an estimated $408K and leaving 114,355 shares worth $22.8M. The position accounts for 0.06% of the portfolio, ranked #215.
Nomura Holdings first reported a position in LGND in Q2 2013 and has held it in 26 quarters since. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- Nomura Holdings held 114,355 shares of Ligand Pharmaceuticals worth $22.8M as of Q1 2026.
- Nomura Holdings sold 2,062 Ligand Pharmaceuticals shares in Q1 2026, an estimated $408K.
- Ligand Pharmaceuticals made up 0.06% of Nomura Holdings's portfolio in Q1 2026, its #215 holding.
- Nomura Holdings first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 26 quarters since.
- 358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on Nomura Holdings's 13F filing for Q1 2026, filed 15 May 2026.